Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion

J Thorac Oncol. 2019 Oct;14(10):e226-e228. doi: 10.1016/j.jtho.2019.05.046.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acrylamides / administration & dosage
  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / secondary
  • Angiopoietin-Like Protein 6
  • Angiopoietin-like Proteins / genetics*
  • Aniline Compounds / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Middle Aged
  • Mutation*
  • Neoplasm Metastasis
  • Oncogene Proteins, Fusion / genetics
  • Prognosis
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / administration & dosage
  • Pyrimidinones / administration & dosage

Substances

  • ANGPTL6 protein, human
  • Acrylamides
  • Angiopoietin-Like Protein 6
  • Angiopoietin-like Proteins
  • Aniline Compounds
  • Oncogene Proteins, Fusion
  • Pyridones
  • Pyrimidinones
  • trametinib
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf